Cytiva—formerly GE Healthcare Life Sciences and now the life science platform of Danaher Corporation—announced at the 5th China International Import Expo (CIIE) an additional investment of RMB 60 million (USD 8.28 million) to establish a China science innovation center. The entity, valued at RMB 100 million (USD 13.79 million) in total capital, will provide comprehensive support for the biopharmaceutical industry, including upstream and downstream products, technologies, services, and innovative solutions. The center will focus on biotechnology research and development, clinical production, incubation of new therapies, talent training, intelligent manufacturing, and regulatory verification.
Product Showcase and Partnerships
At the event, Cytiva showcased its 50-2500L Xcellerex disposable solution preparation bag, Biacore 8K new generation molecular interaction analysis system, and other products. The company also announced partnerships with Zein Bio, Oricell Therapeutics, Obio Technology, and Foster Bio, among others, to further expand its presence in the biopharmaceutical sector.
Partnership with Oricell Therapeutics
Cytiva’s collaboration with Oricell Therapeutics will involve the establishment of a plasmid virus R&D and production platform and a cell therapy GMP compliant production line. Cytiva will provide Oricell Therapeutics with strategic resources in process development, IND filing, clinical sample manufacturing, and industrialization capacity expansion. This partnership aims to enhance the development and production capabilities for innovative cell therapies, contributing to the advancement of personalized medicine.-Fineline Info & Tech
